ArticleRheumatology international2012
Mycophenolate mofetil in juvenile dermatomyositis: a case series.
Article in Rheumatology international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 47 citations in OpenAlex.
- Advances in Juvenile Dermatomyositis: Pathophysiology, Diagnosis, Treatment and Interstitial Lung Diseases-A Narrative Review.Children (Basel, Switzerland) · 2024Review
- [Advances in the diagnostics and treatment of juvenile dermatomyositis].Zeitschrift fur Rheumatologie · 2024Review
- Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care.Nature reviews. Rheumatology · 2023Review
- Updates on Juvenile Dermatomyositis from the Last Decade: Classification to Outcomes.Rheumatic diseases clinics of North America · 2021Review
- JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology.Pediatric rheumatology online journal · 2021Review
- Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.World journal of pediatrics : WJP · 2020Review
- Multispecialty approach for improving outcomes in juvenile dermatomyositis.Journal of multidisciplinary healthcare · 2019Review
- Treatment of Juvenile Dermatomyositis: An Update.Paediatric drugs · 2017Review
- Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms.Clinical reviews in allergy & immunology · 2017Review
- Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies.Rheumatic diseases clinics of North America · 2013Review
- Update in juvenile myositis.Current opinion in rheumatology · 2013Review
- Juvenile dermatomyositis: new insights and new treatment strategies.Therapeutic advances in musculoskeletal disease · 2012Article
- Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.Nature reviews. Rheumatology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to report the use of Mycophenolate Mofetil (MMF) in Juvenile Dermatomyositis (JDM). A retrospective chart review of children diagnosed with JDM having received MMF was performed. Response was evaluated 3 months after the onset of MMF by comparing muscle strength and steroid dosage before and after treatment. A good response was defined by global improvement concerning weakness and fatigability as evaluated subjectively by the physician along with a gain of at least 4 points on each of 2 muscle testings (Manual Muscle Testing, MMT and Childhood Myositis Assessment Score, CMAS) and/or a decrease of >15% of the corticosteroid dosage. Eight patients were identified. Except for one, all had received MMF secondary to an initial therapy of conventional immunosuppressants. Six patients showed good response by our predefined criteria. Changes of muscle testing scores ranged between +0 to +21 points (mean = +10.6) for the MMT and between +3 and +11 (mean = +7) for the CMAS. Corticosteroid tapering varied from 0 to 50%, with a mean of 18%. In most cases, follow-up was available for many months (up to 26); overall, we observed only one complication: a transient neutropenia in a patient concurrently receiving another immunosuppressant. This small series is the first published report on the use of MMF in JDM and suggests it is safe. Prospective larger studies are required to further elucidate the use of MMF in JDM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.